StockData

Monopar Therapeutics vs Mereo BioPharma

MNPR and MREO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How MNPR and MREO compare

Monopar Therapeutics is the larger company, worth 2.0 times as much as Mereo BioPharma ($483M against $244M).

Monopar Therapeutics scores higher on the StockData Score (7 against 1 for Mereo BioPharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricMNPRMREO
Size and price
Market cap$483M$244M
Share price$71.97$0.305
Change, 1 year−17.3%−82.9%
Change, 5 years197%−83.9%
Beta (5Y)0.662.15
Employees2239
StockData Score
Total score7 (better)1
Valuation score00
Growth score00
Performance score1 (better)0
Health score6 (better)1
Dividend score00
Valuation
P/B3.7× (better)10.3×
FCF yield–−9.1%
Profitability
Return on equity−19.5% (better)−76.6%
Financial health
Debt / equity0.00–
Interest coverage–−440.6×
Current ratio33.56 (better)5.22
Altman Z-score69.88 (better)−2.20
Piotroski F-score44
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions92.7%7.1%
Held by insiders–0.18%
Insider net buying, 12 months−$5.6M–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.